Cathay Biotech (SH:688065) Zheng Quan Shi Bao Wang·2025-10-31 05:57Group 1 - The core viewpoint of the articles highlights the strong performance of Kasei Biotech in 2023, with significant revenue and profit growth in the first three quarters [1][2] - Kasei Biotech reported a revenue of 2.545 billion yuan, a year-on-year increase of 14.9%, and a profit of 503 million yuan, reflecting a 29.96% growth [1] - The company's net profit attributable to shareholders reached 450 million yuan, up 30.56% year-on-year, while the non-recurring net profit was 428 million yuan, increasing by 27.83% [1] Group 2 - Kasei Biotech's bio-manufacturing initiatives align with national strategic emerging industries, focusing on low-carbon transformations through bio-based new materials [2] - The company has partnered with industry leaders such as China Merchants Group and CATL to build a bio-manufacturing ecosystem [2] - Kasei Biotech's projects, including a 500 million yuan investment in a bio-based battery shell manufacturing base, are progressing well, indicating strong market demand [1][2]